Clinical Trial Update: Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Palivizumab for prevention of Respiratory Syncytial Virus infection in Japanese newborns, infants, and young children with immunocompro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Palivizumab (Palivizumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Respiratory Syncytial Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2013-06-17